Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
26 Luglio 2024 - 2:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company, today announced that it
will report its second quarter 2024 financial results
on Monday, August 5, 2024, prior to the open of U.S. markets.
The Company’s management will also host a
conference call and webcast at 8:30 am ET on Monday,
August 5, 2024, to discuss the financial results and provide a
business update.
Investors and the general public can access the
live webcast at:
https://www.webcaster4.com/Webcast/Page/3018/50830.
For those unable to listen to the live webcast, a
replay will be available for 30 days on the Investors section of
the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.Krystal
Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology
company focused on the discovery, development and commercialization
of genetic medicines to treat diseases with high unmet medical
needs. VYJUVEK® is the Company’s first commercial product, the
first-ever redosable gene therapy, and the first medicine approved
by the FDA for the treatment of dystrophic epidermolysis bullosa.
The Company is rapidly advancing a robust preclinical and clinical
pipeline of investigational genetic medicines in respiratory,
oncology, dermatology, ophthalmology, and aesthetics. Krystal
Biotech is headquartered in Pittsburgh, Pennsylvania. For more
information, please visit http://www.krystalbio.com, and follow
@KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACTInvestors and
Media:Stéphane Paquette, PhDKrystal
Biotechspaquette@krystalbio.com
Grafico Azioni Krystal Biotech (NASDAQ:KRYS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Krystal Biotech (NASDAQ:KRYS)
Storico
Da Set 2023 a Set 2024